Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Novo Nordisk

Novo Nordisk CEO to face off with Bernie Sanders over 1,300% Ozempic markup in U.S.

Novo's Danish CEO Lars Fruergaard Jørgensen will face the U.S. Senate in September to defend Wegovy's and Ozempic's eye-watering prices.

Fortune

In China, weight-loss drugs are becoming big business

Chinese pharmaceutical companies are racing to roll out weight-loss drugs amid the popularity of Ozempic.

Al Jazeera

George Soros's Fund Sells Uber, Novo Nordisk in Q1 to Focus on AI, Construction, and Apparel Stocks

Soros Fund Management made several changes to its portfolio in Q1, increasing stakes in Alphabet, Nike, and D.R. Horton.

International Business Times UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Women advised to pair effective contraception with ‘skinny jabs’

Amid baby boom reports linked to drugs such as Wegovy and Ozempic, experts say it would be ‘wise’ to take extra precautions

The Guardian - UK

Eli Lilly (LLY) vs. Novo Nordisk (NVO): Which Pharma Stock Is Driving Long-Term 2024 Profits?

The pharmaceutical market is poised for rapid expansion due to rising global medical needs and increasing integration of technologies in drug discovery and development. Amid this, let’s analyze Eli Lilly (LLY) and Novo Nordisk (NVO) to determine which pharma stock will drive long-term profits in 2024. Read more to find…

StockNews.com

It's Time for Over-the-Counter Ozempic

There's an easy way to lower the cost of next-generation weight-loss drugs.

Reason

Nestlé is rolling out a new food brand just for Ozempic and Wegovy users

The company says its Vital Pursuit line, priced under $5, is high in protein and vitamins, addressing nutrient deficiencies that Ozempic and Wegovy users may have.

Fortune

Read news from The Economist, FT, and more,
with one subscription

Hims & Hers’ surprise 85% Wegovy discount is latest step on a journey to make medicine less ‘paternalistic,’ exec says

The compounded weight loss drug starts at $199 per month.

Fortune

Longest Clinical Trial Yet Of Weight Loss Drug Wegovy Reveals Significant Side Effects

A recent clinical trial of Wegovy showed that 17 percent of patients on the drug left the trial because of side effects.

Inverse

Forget Weight-Loss Drugs, Here's the Next Breakthrough Pharma Stock

There is another segment of the pharma industry that is as hot as weight-loss drugs: antibody-drug conjugates, or ADCs. These treatments will, in the near future, replace conventional chemotherapy, thanks to fewer side effects for patients. Even a partial replacement for chemotherapy could make it a $140 billion market -…

Barchart

Decades-old law limits access to Wegovy for Medicaid beneficiaries

New medications like Wegovy are changing the way people lose weight and manage obesity, but many Medicaid beneficiaries can't get them.

WEKU

What is behind the insulin shortage in the US?

Pharma companies are slashing insulin production in favour of more lucrative weight-loss drugs.

Al Jazeera

Danish firm behind weight-loss drug Wegovy raises profit forecast to £15.3bn

Novo Nordisk, which is now Europe’s most valuable company, also reports strong sales of diabetes drug Ozempic

The Guardian - UK

Weight-loss Drug Maker Novo Nordisk's Profits Soar Further

The drugmaker increased its market share of the diabetic treatment market by 1.8 percentage points and now has a 34-percent share of the market.

International Business Times

Get all your
news in one place.

100's of premium titles.
One news app.

Evening Standard

Doctors warn unplanned 'Ozempic babies' may be harmed by weight-loss drugs

Women using weight-loss drug semaglutide have reported surprise pregnancies, but doctors warn the risk to babies is not yet clear

WEKU

Persistent shortage of growth hormone frustrates parents and clinicians

As a shortage of growth hormone used to treat rare diseases in children drags on, families and doctors are struggling with insurers' requirements to get prescriptions filled.

Barchart

3 Best Mega-Cap Stocks for Dividend Investors

Discover the compelling stories behind three mega-cap dividend stocks that have caught the attention of analysts and investors alike.

StockNews.com

Canopy Growth (CGC) vs. Novo Nordisk (NVO): Which Pharma Stock Is a Better Investment?

The Pharma sector’s innovative trial methodologies and shift toward customized medicine signal transformative growth potential in the pharmaceutical industry. While leading Pharma stocks Canopy Growth (CGC) and Novo Nordisk (NVO) stand to benefit, let us analyze which of them is a better investment.

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK

Study: ‘gamechanger’ diabetes drugs cost up to 400 times more than needed

Drug companies urged to ‘release stranglehold’ on medicines such as Ozempic and Trulicity, as millions are priced out of treatment

Barchart

Up 68% in 1 Year, Is Novo Nordisk Stock Still a Buy?

Novo Nordisk is a blue-chip healthcare stock that has delivered game-changing returns to shareholders in the past two decades. Is NVO stock still a good buy?

International Business Times

Nvidia, Novo Nordisk Forge Path To Medical Breakthroughs With AI Supercomputer Gefion

Nvidia and Novo Nordisk's joint venture, Gefion, represents a groundbreaking endeavor in medical research, leveraging AI technology.

Top News

FDA Approves Novo Nordisk's Wegovy For Lowering Heart Risks

FDA approves Novo Nordisk's Wegovy for reducing heart risks in weight management. Novo Nordisk's innovative solution targets weight management and heart risks.

WEKU

FDA approves Wegovy for lowering heart attack and stroke risk in overweight patients

International Business Times

US FDA Approves Wegovy To Cut Risk Of Heart Problems

The US Food and Drug Administration has given the green light for a popular anti-obesity drug to be used to prevent serious heart conditions for the first time, in a move likely to expand insurance coverage.

1 … 17 18 19 20

People

Lars Fruergaard Jørgensen

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.